Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,918.50
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.34
(
0.73%
)
Bitcoin
76,213.65
(
0.42%
)
News Focus
News Focus
Post# of 257431
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 234154

Monday, 08/10/2020 5:54:02 PM

Monday, August 10, 2020 5:54:02 PM

Post# of 257431
LGND-PFNX PR:

https://finance.yahoo.com/news/ligand-acquire-pfenex-inc-213600493.html

Ligand Pharmaceuticals Incorporated and Pfenex Inc. today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis. In addition, Ligand will pay $2.00 per share or $78 million as a Contingent Value Right (CVR) in the event a predefined regulatory milestone is achieved by December 31, 2021…

The $12 price is a 57% premium to today’s 4pm-ET close.

The PR doesn’t specify the regulatory milestone that will trigger payment of the $2/sh CVR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today